Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML1385

Sigma-Aldrich

Lomitapide

≥98% (HPLC)

Synonym(s):

AEGR-733, BMS-201038, N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C39H37F6N3O2
CAS Number:
182431-12-5
Molecular Weight:
693.72
MDL number:
MFCD16620494
UNSPSC Code:
51111800
PubChem Substance ID:
329825833
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(NCC(F)(F)F)C1(C(C=CC=C2)=C2C3=C1C=CC=C3)CCCCN(CC4)CCC4NC(C5=C(C6=CC=C(C(F)(F)F)C=C6)C=CC=C5)=O

InChI

1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)

InChI key

MBBCVAKAJPKAKM-UHFFFAOYSA-N

Gene Information

human ... MTTP(4547) , P4HB(5034)

Application

Lomitapide has been used as a microsomal triglyceride transfer protein (MTP) inhibitor to study its effects on very-low-density lipoproteins (VLDL) export in mouse hepatocytes.

Biochem/physiol Actions

Lomitapide can lower the secretion of very-low-density lipoproteins (VLDL) and chylomicrons.
Lomitapide is an inhibitor of microsomal triglyceride transfer protein (MTP). Lomitapide has been shown to be highly effective in reducing LDL-cholesterol and triglycerides, and has been aproved for treatment of homozygous familial hypercholesterolemia.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly
Simon J, et al.
Cell Metabolism, 31(3), 605-622 (2020)
Severe hypertriglyceridemia with pancreatitis: thirteen years? treatment with lomitapide
Sacks F M, et al.
JAMA Internal Medicine, 174(3), 443-447 (2014)
Frank M Sacks et al.
JAMA internal medicine, 174(3), 443-447 (2013-12-25)
Recurrent pancreatitis is a potentially fatal complication of severe hypertriglyceridemia. Genetic defects and lifestyle risk factors may render this condition unresponsive to current treatments. We report this first case of long-term management of intractable near-fatal recurrent pancreatitis secondary to severe
Jorge Simon et al.
Cell metabolism, 31(3), 605-622 (2020-02-23)
Non-alcoholic steatohepatitis (NASH) is characterized by the accumulation of hepatic fat in an inflammatory/fibrotic background. Herein, we show that the hepatic high-activity glutaminase 1 isoform (GLS1) is overexpressed in NASH. Importantly, GLS1 inhibition reduces lipid content in choline and/or methionine

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service